(S)-naringenin decreases expression EXP 6480464 naringenin results in decreased expression of LRRK2 mRNA CTD PMID:34655599 (S)-naringenin multiple interactions EXP 6480464 naringenin inhibits the reaction [Paraquat results in decreased expression of LRRK2 mRNA] CTD PMID:34655599 1,1-dichloroethene decreases expression ISO RGD:1557751 6480464 vinylidene chloride results in decreased expression of LRRK2 mRNA CTD PMID:26682919 1,2-dimethylhydrazine multiple interactions ISO RGD:1557751 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of LRRK2 mRNA CTD PMID:22206623 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of LRRK2 mRNA CTD PMID:22298810 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of LRRK2 mRNA CTD PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1557751 6480464 Tetrachlorodibenzodioxin results in decreased expression of LRRK2 mRNA CTD PMID:33956508 3-methyladenine multiple interactions ISO RGD:1353141 6480464 3-methyladenine inhibits the reaction [LRRK2 gene mutant form results in increased susceptibility to 1-Methyl-4-phenylpyridinium] CTD PMID:25017139 4-hydroxyphenyl retinamide increases expression ISO RGD:1557751 6480464 Fenretinide results in increased expression of LRRK2 mRNA CTD PMID:28973697 6-propyl-2-thiouracil decreases expression EXP 6480464 Propylthiouracil results in decreased expression of LRRK2 mRNA CTD PMID:24780913 acetamide increases expression EXP 6480464 acetamide results in increased expression of LRRK2 mRNA CTD PMID:31881176 acrylamide multiple interactions ISO RGD:1557751 6480464 Acrylamide promotes the reaction [NFATC2 protein binds to LRRK2 protein] more ... CTD PMID:37037409 acrylamide increases expression ISO RGD:1557751 6480464 Acrylamide results in increased expression of LRRK2 mRNA, Acrylamide results in increased expression of LRRK2 protein CTD PMID:37037409 aflatoxin B1 decreases methylation ISO RGD:1353141 6480464 Aflatoxin B1 results in decreased methylation of LRRK2 gene CTD PMID:27153756 Aflatoxin B2 alpha increases methylation ISO RGD:1353141 6480464 aflatoxin B2 results in increased methylation of LRRK2 intron CTD PMID:30157460 all-trans-retinoic acid increases expression ISO RGD:1353141 6480464 Tretinoin results in increased expression of LRRK2 mRNA CTD PMID:33167477 amphetamine increases expression EXP 6480464 Amphetamine results in increased expression of LRRK2 mRNA CTD PMID:30779732 arsenite(3-) increases phosphorylation ISO RGD:1557751 6480464 arsenite results in increased phosphorylation of LRRK2 protein CTD PMID:33053406 bafilomycin A1 increases response to substance ISO RGD:1353141 6480464 LRRK2 gene mutant form results in increased susceptibility to bafilomycin A1 CTD PMID:25017139 benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of LRRK2 mRNA CTD PMID:21839799 benzo[a]pyrene decreases methylation ISO RGD:1557751 6480464 Benzo(a)pyrene results in decreased methylation of LRRK2 intron CTD PMID:27901495 benzo[a]pyrene affects methylation ISO RGD:1353141 6480464 Benzo(a)pyrene affects the methylation of LRRK2 intron CTD PMID:30157460 benzo[e]pyrene increases methylation ISO RGD:1353141 6480464 benzo(e)pyrene results in increased methylation of LRRK2 intron CTD PMID:30157460 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of LRRK2 gene CTD PMID:28505145 bisphenol A decreases methylation ISO RGD:1353141 6480464 bisphenol A results in decreased methylation of LRRK2 gene CTD PMID:31601247 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of LRRK2 mRNA CTD PMID:34947998 bisphenol A increases expression ISO RGD:1557751 6480464 bisphenol A results in increased expression of LRRK2 mRNA CTD PMID:33221593 butanal decreases expression ISO RGD:1353141 6480464 butyraldehyde results in decreased expression of LRRK2 mRNA CTD PMID:26079696 cadmium atom decreases expression ISO RGD:1353141 6480464 Cadmium results in decreased expression of LRRK2 mRNA CTD PMID:21120746 cadmium atom increases expression EXP 6480464 Cadmium results in increased expression of LRRK2 mRNA CTD PMID:34816377 cadmium atom multiple interactions EXP 6480464 Acetylcysteine inhibits the reaction [Cadmium results in increased expression of LRRK2 mRNA] CTD PMID:34816377 cadmium atom multiple interactions ISO RGD:1353141 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of LRRK2 mRNA CTD PMID:35301059 cadmium dichloride multiple interactions ISO RGD:1353141 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of LRRK2 mRNA CTD PMID:35301059 carbon nanotube increases expression ISO RGD:1557751 6480464 Nanotubes more ... CTD PMID:25554681 CGP 52608 multiple interactions ISO RGD:1353141 6480464 CGP 52608 promotes the reaction [RORA protein binds to LRRK2 gene] CTD PMID:28238834 chlorpyrifos decreases expression ISO RGD:1557751 6480464 Chlorpyrifos results in decreased expression of LRRK2 mRNA CTD PMID:29156651 , PMID:37019170 cisplatin decreases expression ISO RGD:1353141 6480464 Cisplatin results in decreased expression of LRRK2 mRNA CTD PMID:27392435 cisplatin multiple interactions ISO RGD:1353141 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of LRRK2 mRNA CTD PMID:27392435 clozapine increases expression ISO RGD:1353141 6480464 Clozapine results in increased expression of LRRK2 protein CTD PMID:34122009 copper(II) sulfate affects expression ISO RGD:1353141 6480464 Copper Sulfate affects the expression of LRRK2 mRNA CTD PMID:19549813 corticosterone multiple interactions ISO RGD:1557751 6480464 LRRK2 protein mutant form promotes the reaction [Paraquat results in increased secretion of Corticosterone] CTD PMID:31174552 corticosterone increases secretion ISO RGD:1557751 6480464 LRRK2 protein mutant form results in increased secretion of Corticosterone, LRRK2 protein results in increased secretion of Corticosterone CTD PMID:31174552 crocidolite asbestos decreases expression ISO RGD:1557751 6480464 Asbestos, Crocidolite results in decreased expression of LRRK2 mRNA CTD PMID:29279043 dimethylarsinic acid multiple interactions ISO RGD:1557751 6480464 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LRRK2 mRNA CTD PMID:34876320 dioxygen increases expression ISO RGD:1353141 6480464 Oxygen deficiency results in increased expression of LRRK2 mRNA CTD PMID:26516004 dopamine multiple interactions ISO RGD:1353141 6480464 LRRK2 mutant form results in increased susceptibility to [Dopamine co-treated with SLC6A3 protein] CTD PMID:23628791 dorsomorphin multiple interactions ISO RGD:1353141 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRK2 mRNA CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1353141 6480464 Doxorubicin results in decreased expression of LRRK2 mRNA CTD PMID:29803840 endosulfan affects expression EXP 6480464 Endosulfan affects the expression of LRRK2 mRNA CTD PMID:29391264 ethanol affects expression ISO RGD:1557751 6480464 Ethanol affects the expression of LRRK2 mRNA CTD PMID:30319688 ethanol affects splicing ISO RGD:1557751 6480464 Ethanol affects the splicing of LRRK2 mRNA CTD PMID:30319688 ethyl methanesulfonate increases expression ISO RGD:1353141 6480464 Ethyl Methanesulfonate results in increased expression of LRRK2 mRNA CTD PMID:23649840 fenamidone increases expression ISO RGD:1557751 6480464 fenamidone results in increased expression of LRRK2 mRNA CTD PMID:27029645 folic acid multiple interactions ISO RGD:1557751 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of LRRK2 mRNA CTD PMID:22206623 furan increases expression EXP 6480464 furan results in increased expression of LRRK2 mRNA CTD PMID:27387713 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of LRRK2 mRNA CTD PMID:33387578 GTP multiple interactions ISO RGD:1353141 6480464 sodium arsenite inhibits the reaction [LRRK2 protein binds to Guanosine Triphosphate] CTD PMID:24942733 GTP affects binding ISO RGD:1353141 6480464 LRRK2 protein binds to Guanosine Triphosphate CTD PMID:24942733 hydrogen peroxide increases response to substance ISO RGD:1557751 6480464 LRRK2 protein results in increased susceptibility to Hydrogen Peroxide CTD PMID:19692353 hydrogen peroxide decreases phosphorylation ISO RGD:1353141 6480464 Hydrogen Peroxide results in decreased phosphorylation of LRRK2 protein, Hydrogen Peroxide results in decreased phosphorylation of LRRK2 protein mutant form CTD PMID:24942733 lactacystin increases ubiquitination ISO RGD:1353141 6480464 lactacystin results in increased ubiquitination of LRRK2 protein CTD PMID:24942733 lead(0) increases expression EXP 6480464 Lead results in increased expression of LRRK2 mRNA CTD PMID:34816377 lead(0) multiple interactions EXP 6480464 Acetylcysteine inhibits the reaction [Lead results in increased expression of LRRK2 mRNA] CTD PMID:34816377 lipopolysaccharide increases expression ISO RGD:1557751 6480464 Lipopolysaccharides results in increased expression of LRRK2 mRNA, Lipopolysaccharides results in increased expression of LRRK2 protein CTD PMID:30720180 lipopolysaccharide multiple interactions ISO RGD:1353141 6480464 [S-(1 more ... CTD PMID:35811015 lipopolysaccharide decreases expression ISO RGD:1353141 6480464 Lipopolysaccharides results in decreased expression of LRRK2 mRNA CTD PMID:35811015 lipopolysaccharide multiple interactions ISO RGD:1557751 6480464 LRRK2 protein affects the reaction [Lipopolysaccharides results in decreased expression of SLC6A3 protein] more ... CTD PMID:32247534 luteolin multiple interactions ISO RGD:1557751 6480464 [Rotenone co-treated with Luteolin] results in increased expression of LRRK2 mRNA, Luteolin inhibits the reaction [Rotenone results in increased expression of LRRK2 mRNA] CTD PMID:30207190 maneb multiple interactions ISO RGD:1557751 6480464 [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA more ... CTD PMID:23017109 maneb multiple interactions ISO RGD:1353141 6480464 3-(4-(morpholin-4-yl)-7H-pyrrolo(2 more ... CTD PMID:34897981 manganese atom increases response to substance ISO RGD:1353141 6480464 LRRK2 mutant form results in increased susceptibility to Manganese CTD PMID:23628791 manganese atom multiple interactions ISO RGD:1353141 6480464 LRRK2 mutant form results in increased susceptibility to [Manganese co-treated with SLC6A3 protein] CTD PMID:23628791 manganese(0) increases response to substance ISO RGD:1353141 6480464 LRRK2 mutant form results in increased susceptibility to Manganese CTD PMID:23628791 manganese(0) multiple interactions ISO RGD:1353141 6480464 LRRK2 mutant form results in increased susceptibility to [Manganese co-treated with SLC6A3 protein] CTD PMID:23628791 methapyrilene increases methylation ISO RGD:1353141 6480464 Methapyrilene results in increased methylation of LRRK2 intron CTD PMID:30157460 methoxychlor affects methylation EXP 6480464 Methoxychlor affects the methylation of LRRK2 gene CTD PMID:35440735 methylarsonic acid multiple interactions ISO RGD:1557751 6480464 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LRRK2 mRNA CTD PMID:34876320 N,N-diethyl-m-toluamide multiple interactions EXP 6480464 [Permethrin co-treated with DEET] results in increased methylation of LRRK2 gene CTD PMID:33148267 N-acetyl-L-cysteine multiple interactions ISO RGD:1353141 6480464 Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein] CTD PMID:34897981 N-acetyl-L-cysteine multiple interactions EXP 6480464 Acetylcysteine inhibits the reaction [Cadmium results in increased expression of LRRK2 mRNA], Acetylcysteine inhibits the reaction [Lead results in increased expression of LRRK2 mRNA] CTD PMID:34816377 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal increases ubiquitination ISO RGD:1353141 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of LRRK2 protein CTD PMID:24942733 N-methyl-4-phenylpyridinium multiple interactions ISO RGD:1353141 6480464 1-Methyl-4-phenylpyridinium promotes the reaction [LRRK2 gene mutant form results in increased activity of CASP3 protein] more ... CTD PMID:25017139 more ... N-methyl-4-phenylpyridinium increases expression ISO RGD:1353141 6480464 1-Methyl-4-phenylpyridinium results in increased expression of LRRK2 mRNA, 1-Methyl-4-phenylpyridinium results in increased expression of LRRK2 protein CTD PMID:30720180 N-methyl-4-phenylpyridinium increases response to substance ISO RGD:1353141 6480464 LRRK2 gene mutant form results in increased susceptibility to 1-Methyl-4-phenylpyridinium, LRRK2 protein mutant form results in increased susceptibility to 1-Methyl-4-phenylpyridinium CTD PMID:25017139 , PMID:26930193 nickel atom decreases expression ISO RGD:1353141 6480464 Nickel results in decreased expression of LRRK2 mRNA CTD PMID:23195993 paracetamol decreases expression ISO RGD:1353141 6480464 Acetaminophen results in decreased expression of LRRK2 mRNA CTD PMID:29067470 paracetamol decreases expression EXP 6480464 Acetaminophen results in decreased expression of LRRK2 mRNA CTD PMID:33387578 paraquat decreases response to substance ISO RGD:1353141 6480464 LRRK2 protein mutant form results in decreased susceptibility to Paraquat, LRRK2 protein results in decreased susceptibility to Paraquat CTD PMID:19625511 , PMID:26020005 paraquat multiple interactions EXP 6480464 naringenin inhibits the reaction [Paraquat results in decreased expression of LRRK2 mRNA] CTD PMID:34655599 paraquat decreases expression EXP 6480464 Paraquat results in decreased expression of LRRK2 mRNA CTD PMID:34655599 paraquat multiple interactions ISO RGD:1353141 6480464 3-(4-(morpholin-4-yl)-7H-pyrrolo(2 more ... CTD PMID:34897981 paraquat affects response to substance ISO RGD:1557751 6480464 LRRK2 protein affects the susceptibility to Paraquat CTD PMID:32247534 paraquat increases response to substance ISO RGD:1557751 6480464 LRRK2 protein results in increased susceptibility to Paraquat CTD PMID:31174552 paraquat multiple interactions ISO RGD:1557751 6480464 [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA more ... CTD PMID:23017109 more ... pentanal decreases expression ISO RGD:1353141 6480464 pentanal results in decreased expression of LRRK2 mRNA CTD PMID:26079696 perfluorooctane-1-sulfonic acid decreases expression ISO RGD:1353141 6480464 perfluorooctane sulfonic acid results in decreased expression of LRRK2 mRNA CTD PMID:27153767 permethrin multiple interactions EXP 6480464 [Permethrin co-treated with DEET] results in increased methylation of LRRK2 gene CTD PMID:33148267 pirinixic acid multiple interactions ISO RGD:1353141 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of LRRK2 mRNA CTD PMID:19710929 pirinixic acid increases expression ISO RGD:1557751 6480464 pirinixic acid results in increased expression of LRRK2 mRNA CTD PMID:20813756 resveratrol multiple interactions ISO RGD:1353141 6480464 [Plant Extracts co-treated with Resveratrol] results in increased expression of LRRK2 mRNA CTD PMID:23557933 rotenone decreases response to substance ISO RGD:1353141 6480464 LRRK2 protein results in decreased susceptibility to Rotenone CTD PMID:19625511 , PMID:20067578 rotenone increases expression ISO RGD:1557751 6480464 Rotenone results in increased expression of LRRK2 mRNA CTD PMID:30207190 rotenone multiple interactions ISO RGD:1557751 6480464 [Rotenone co-treated with Luteolin] results in increased expression of LRRK2 mRNA, Luteolin inhibits the reaction [Rotenone results in increased expression of LRRK2 mRNA] CTD PMID:30207190 rotenone affects expression EXP 6480464 Rotenone affects the expression of LRRK2 mRNA CTD PMID:31814881 rotenone multiple interactions ISO RGD:1353141 6480464 PMK-1 protein affects the reaction [LRRK2 protein results in decreased susceptibility to Rotenone] more ... CTD PMID:19741132 , PMID:20067578 rotenone increases response to substance ISO RGD:1353141 6480464 LRRK2 gene polymorphism results in increased susceptibility to Rotenone, LRRK2 protein results in increased susceptibility to Rotenone CTD PMID:19692353 , PMID:19741132 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions ISO RGD:1353141 6480464 [S-(1 more ... CTD PMID:35811015 SB 431542 multiple interactions ISO RGD:1353141 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRK2 mRNA CTD PMID:27188386 sodium arsenate multiple interactions ISO RGD:1557751 6480464 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LRRK2 mRNA CTD PMID:34876320 sodium arsenite multiple interactions ISO RGD:1557751 6480464 [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LRRK2 mRNA CTD PMID:34876320 sodium arsenite multiple interactions ISO RGD:1353141 6480464 sodium arsenite inhibits the reaction [LRRK2 protein binds to Guanosine Triphosphate] more ... CTD PMID:24942733 sodium arsenite decreases phosphorylation ISO RGD:1353141 6480464 sodium arsenite results in decreased phosphorylation of LRRK2 protein mutant form CTD PMID:24942733 sulforaphane decreases expression ISO RGD:1557751 6480464 sulforaphane results in decreased expression of LRRK2 mRNA CTD PMID:30529165 sunitinib decreases expression ISO RGD:1353141 6480464 Sunitinib results in decreased expression of LRRK2 mRNA CTD PMID:31533062 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of LRRK2 mRNA CTD PMID:34492290 titanium dioxide increases methylation ISO RGD:1353141 6480464 titanium dioxide results in increased methylation of LRRK2 promoter CTD PMID:34973136 trichloroethene multiple interactions EXP 6480464 Trichloroethylene results in increased activity of and results in increased phosphorylation of LRRK2 protein CTD PMID:33636387 trichostatin A increases expression ISO RGD:1353141 6480464 trichostatin A results in increased expression of LRRK2 mRNA CTD PMID:24935251 trimellitic anhydride increases expression ISO RGD:1557751 6480464 trimellitic anhydride results in increased expression of LRRK2 mRNA CTD PMID:19042947 tris(2-butoxyethyl) phosphate affects expression ISO RGD:1353141 6480464 tris(2-butoxyethyl) phosphate affects the expression of LRRK2 mRNA CTD PMID:29024780 trovafloxacin decreases expression ISO RGD:1557751 6480464 trovafloxacin results in decreased expression of LRRK2 mRNA CTD PMID:35537566 tungsten decreases expression ISO RGD:1557751 6480464 Tungsten results in decreased expression of LRRK2 mRNA CTD PMID:30912803 valproic acid decreases methylation ISO RGD:1353141 6480464 Valproic Acid results in decreased methylation of LRRK2 gene CTD PMID:29154799 valproic acid increases expression ISO RGD:1353141 6480464 Valproic Acid results in increased expression of LRRK2 mRNA CTD PMID:26272509 valproic acid multiple interactions ISO RGD:1353141 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRK2 mRNA CTD PMID:27188386 zoledronic acid decreases expression ISO RGD:1353141 6480464 zoledronic acid results in decreased expression of LRRK2 mRNA CTD PMID:24714768